Tissue-repair research comparison
BPC-157 vs BPC-157 + TB-500 Blend
A preclinical evidence comparison covering material identity, the 2026 rat Achilles-tendon experiment and why combination findings do not establish human recovery outcomes.
Editorial answer
The short answer
The best directly matching comparison is a small exploratory rat study. It reported no additive benefit for the combination over either agent alone, and it provides no controlled human efficacy or safety evidence.
Research and evidence interpretation only. No usage or dosing guidance.Structured comparison
Compare like with like
Every difference includes an interpretation note so a molecular or protocol distinction is not converted into a marketing claim.
Swipe horizontally to compare every column
| Question | BPC-157 | BPC-157 + TB-500 Blend | Editorial interpretation |
|---|---|---|---|
| Material definition | Single synthetic 15-amino-acid peptide | Two-component mixture; TB-500 naming may refer to an acetylated thymosin-β4 fragment or be used inconsistently | A blend requires component identity and quantitative ratio controls. |
| Direct comparative evidence | Included as one arm in a 32-rat Achilles-tendon study | Combination arm included in the same study | Eight rats per group; intraperitoneal exposure for four weeks. |
| Biomechanical result | Maximum load was numerically higher than control but not statistically significant | The abstract did not report an additive biomechanical advantage | TB-500 alone reached statistical significance for maximum load in this experiment. |
| Histology result | Numerically lower total scores without significance for the reported total scores | Lower total Movin score versus control (p=0.040) | Combination did not confer additional benefit over either agent alone. |
| Human evidence | No adequate controlled human efficacy evidence identified | No controlled human combination evidence identified | Animal tendon findings cannot establish human recovery or dosing. |
Evidence cards
What the linked records actually report
Findings remain attached to the study population, experimental model and source type.
Thirty-two male rats were randomized to control, BPC-157, TB-500 or the combination for four weeks after Achilles transection and repair.
Exploratory animal model with eight animals per group.Open source ↗The authors reported no additional benefit from combined BPC-157 and TB-500 compared with either agent alone.
The finding applies only to the stated rat model, exposure and endpoints.Open source ↗An analytical publication identified TB-500 as an N-terminal acetylated thymosin-β4 17–23 fragment in a seized product.
Other catalogs may use TB-500 differently; the supplied sequence must be documented.Open source ↗Translation boundary
What this comparison cannot establish
- That the blend is superior to BPC-157 alone.
- That rat histology predicts human injury recovery.
- That a trade-style TB-500 name defines the sequence, ratio, purity or sterility of a catalog blend.
Sources
References used for this comparison
- 01Randomized rat study
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats
Biçer O, et al. Jt Dis Relat Surg. 2026;37:822–837. PMID 42542926.
- 02Systematic review
Emerging Use of BPC-157 in Orthopaedic Sports Medicine
Systematic review. 2025. PMID 40756949.
- 03Analytical identity
N-terminal acetylated thymosin beta 4 fragment identified in TB-500
Analytical study. 2012. PMID 22962027.
- 04Clinical evidence review
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Evidence review. 2026. PMID 41476424.
Editorial analysis
Read the product-specific source reviews
These articles expand individual identity, trial and evidence questions without changing the comparison conclusions above.
BPC-157 + TB-500 in the 2026 Rat Achilles Tendon Study: A Close Reading
A source-led analysis of the 2026 BPC-157 and TB-500 rat Achilles tendon study, including group design, histology, biomechanics and the absence of an added…
Read source review →BPC-157 and TB-500 Evidence Boundaries: Human Data, FDA Concerns and Quality Questions
A critical review of the limited human evidence for BPC-157 and TB-500, current FDA-identified safety information gaps and the quality questions a research catalog…
Read source review →Comparison FAQ
Questions this page is designed to answer
Did the 2026 rat study show that the combination was better?
No. The authors explicitly reported no additional benefit for combined BPC-157 and TB-500 compared with either agent alone.
Are there controlled human trials of the exact blend?
No adequate controlled human trial of the exact catalog combination was identified for this review.
Continue researching